T2 Biosystems extends multi-year supplier agreement with Vizient

T2 Biosystems (TTOO) announced that its multi-year capital equipment supplier agreement with Vizient has been extended through March 31, 2026. The products covered under the contract with Vizient include the T2Dx Instrument, the T2Bacteria Panel and the T2Candida Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood. Through the extended contract, Vizient members will continue to have access to broader exposure and contracted pricing for the T2Dx Instrument, the T2Bacteria Panel and the T2Candida Panel, the only FDA-cleared products able to detect sepsis-causing pathogens directly from whole blood.